Investors & Media
News
SAGE Therapeutics to Participate in the Goldman Sachs 36th Annual Global Healthcare Conference
The live webcast can be accessed on the investor page of SAGE's website at investor.sagerx.com. A replay of the webcast will also be archived on SAGE's website following the conference.
About
Forward-Looking Statements
Various statements in this release concerning SAGE's future expectations, plans and prospects, including without limitation, SAGE's expectations regarding SAGE-547 as a treatment for SRSE, essential tremor and severe postpartum depression constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. It should be noted that there is only limited data concerning the safety and efficacy of SAGE-547. These data may not be repeated or observed in future trials involving SAGE-547. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, SAGE's ability to successfully demonstrate the efficacy and safety of its drug candidates, the pre-clinical and clinical results for its product candidates, which may
not support further development of product candidates, actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials, obtaining, maintaining and protecting intellectual property, SAGE's ability to enforce its patents against infringers and defend its patent portfolio against challenges from third parties, competition from others developing products for similar uses, SAGE's ability to manage operating expenses, SAGE's ability to obtain additional funding to support its business activities and establish and maintain strategic business alliances and new business initiatives, SAGE's dependence on third parties for development, manufacture, marketing, sales and distribution of products, the outcome of litigation, and unexpected expenditures, as well as those risks more fully discussed in the section entitled "Risk Factors" in SAGE's annual report on
Form 10-K for the fiscal year ended
CONTACT: Investor Contact:Source:Paul Cox ,SAGE Therapeutics paul.cox@sagerx.com 617-299-8377 Media Contact:Dan Budwick ,Pure Communications dan@purecommunicationsinc.com 973-271-6085
News Provided by Acquire Media